Adaptive sampling in two-phase designs: a biomarker study for progression in arthritis.
Ontology highlight
ABSTRACT:
SUBMITTER: McIsaac MA
PROVIDER: S-EPMC4691319 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature
Publications
Adaptive sampling in two-phase designs: a biomarker study for progression in arthritis.
McIsaac Michael A MA Cook Richard J RJ
Statistics in medicine 20150507 21
Response-dependent two-phase designs are used increasingly often in epidemiological studies to ensure sampling strategies offer good statistical efficiency while working within resource constraints. Optimal response-dependent two-phase designs are difficult to implement, however, as they require specification of unknown parameters. We propose adaptive two-phase designs that exploit information from an internal pilot study to approximate the optimal sampling scheme for an analysis based on mean s ...[more]
Similar Datasets
Project description:In biomedical cohort studies for assessing the association between an outcome variable and a set of covariates, usually, some covariates can only be measured on a subgroup of study subjects. An important design question is-which subjects to select into the subgroup to increase statistical efficiency. When the outcome is binary, one may adopt a case-control sampling design or a balanced case-control design where cases and controls are further matched on a small number of complete discrete covariates. While the latter achieves success in estimating odds ratio (OR) parameters for the matching covariates, similar two-phase design options have not been explored for the remaining covariates, especially the incompletely collected ones. This is of great importance in studies where the covariates of interest cannot be completely collected. To this end, assuming that an external model is available to relate the outcome and complete covariates, we propose a novel sampling scheme that oversamples cases and controls with worse goodness-of-fit based on the external model and further matches them on complete covariates similarly to the balanced design. We develop a pseudolikelihood method for estimating OR parameters. Through simulation studies and explorations in a real-cohort study, we find that our design generally leads to reduced asymptotic variances of the OR estimates and the reduction for the matching covariates is comparable to that of the balanced design.
| S-EPMC7042058 | biostudies-literature
Project description:BackgroundPersonalized medicine is a growing area of research which aims to tailor the treatment given to a patient according to one or more personal characteristics. These characteristics can be demographic such as age or gender, or biological such as a genetic or other biomarker. Prior to utilizing a patient's biomarker information in clinical practice, robust testing in terms of analytical validity, clinical validity and clinical utility is necessary. A number of clinical trial designs have been proposed for testing a biomarker's clinical utility, including Phase II and Phase III clinical trials which aim to test the effectiveness of a biomarker-guided approach to treatment; these designs can be broadly classified into adaptive and non-adaptive. While adaptive designs allow planned modifications based on accumulating information during a trial, non-adaptive designs are typically simpler but less flexible.Methods and findingsWe have undertaken a comprehensive review of biomarker-guided adaptive trial designs proposed in the past decade. We have identified eight distinct biomarker-guided adaptive designs and nine variations from 107 studies. Substantial variability has been observed in terms of how trial designs are described and particularly in the terminology used by different authors. We have graphically displayed the current biomarker-guided adaptive trial designs and summarised the characteristics of each design.ConclusionsOur in-depth overview provides future researchers with clarity in definition, methodology and terminology for biomarker-guided adaptive trial designs.
| S-EPMC4766245 | biostudies-literature
Project description:Two-phase outcome-dependent sampling (ODS) designs are useful when resource constraints prohibit expensive exposure ascertainment on all study subjects. One class of ODS designs for longitudinal binary data stratifies subjects into three strata according to those who experience the event at none, some, or all follow-up times. For time-varying covariate effects, exclusively selecting subjects with response variation can yield highly efficient estimates. However, if interest lies in the association of a time-invariant covariate, or the joint associations of time-varying and time-invariant covariates with the outcome, then the optimal design is unknown. Therefore, we propose a class of two-wave two-phase ODS designs for longitudinal binary data. We split the second-phase sample selection into two waves, between which an interim design evaluation analysis is conducted. The interim design evaluation analysis uses first-wave data to conduct a simulation-based search for the optimal second-wave design that will improve the likelihood of study success. Although we focus on longitudinal binary response data, the proposed design is general and can be applied to other response distributions. We believe that the proposed designs can be useful in settings where (1) the expected second-phase sample size is fixed and one must tailor stratum-specific sampling probabilities to maximize estimation efficiency, or (2) relative sampling probabilities are fixed across sampling strata and one must tailor sample size to achieve a desired precision. We describe the class of designs, examine finite sampling operating characteristics, and apply the designs to an exemplar longitudinal cohort study, the Lung Health Study.
| S-EPMC8110123 | biostudies-literature
Project description:Biomarker-guided treatment is a rapidly developing area of medicine, where treatment choice is personalised according to one or more of an individual's biomarker measurements. A number of biomarker-guided trial designs have been proposed in the past decade, including both adaptive and non-adaptive trial designs which test the effectiveness of a biomarker-guided approach to treatment with the aim of improving patient health. A better understanding of them is needed as challenges occur both in terms of trial design and analysis. We have undertaken a comprehensive literature review based on an in-depth search strategy with a view to providing the research community with clarity in definition, methodology and terminology of the various biomarker-guided trial designs (both adaptive and non-adaptive designs) from a total of 211 included papers. In the present paper, we focus on non-adaptive biomarker-guided trial designs for which we have identified five distinct main types mentioned in 100 papers. We have graphically displayed each non-adaptive trial design and provided an in-depth overview of their key characteristics. Substantial variability has been observed in terms of how trial designs are described and particularly in the terminology used by different authors. Our comprehensive review provides guidance for those designing biomarker-guided trials.
| S-EPMC5374391 | biostudies-literature
Project description:BackgroundWhile random forests are one of the most successful machine learning methods, it is necessary to optimize their performance for use with datasets resulting from a two-phase sampling design with a small number of cases-a common situation in biomedical studies, which often have rare outcomes and covariates whose measurement is resource-intensive.MethodsUsing an immunologic marker dataset from a phase III HIV vaccine efficacy trial, we seek to optimize random forest prediction performance using combinations of variable screening, class balancing, weighting, and hyperparameter tuning.ResultsOur experiments show that while class balancing helps improve random forest prediction performance when variable screening is not applied, class balancing has a negative impact on performance in the presence of variable screening. The impact of the weighting similarly depends on whether variable screening is applied. Hyperparameter tuning is ineffective in situations with small sample sizes. We further show that random forests under-perform generalized linear models for some subsets of markers, and prediction performance on this dataset can be improved by stacking random forests and generalized linear models trained on different subsets of predictors, and that the extent of improvement depends critically on the dissimilarities between candidate learner predictions.ConclusionIn small datasets from two-phase sampling design, variable screening and inverse sampling probability weighting are important for achieving good prediction performance of random forests. In addition, stacking random forests and simple linear models can offer improvements over random forests.
| S-EPMC8607560 | biostudies-literature
Project description:Simon's optimal two-stage design has been widely used in early phase clinical trials for Oncology and AIDS studies with binary endpoints. With this approach, the second-stage sample size is fixed when the trial passes the first stage with sufficient activity. Adaptive designs, such as those due to Banerjee and Tsiatis (2006) and Englert and Kieser (2013), are flexible in the sense that the second-stage sample size depends on the response from the first stage, and these designs are often seen to reduce the expected sample size under the null hypothesis as compared with Simon's approach. An unappealing trait of the existing designs is that they are not associated with a second-stage sample size, which is a non-increasing function of the first-stage response rate. In this paper, an efficient intelligent process, the branch-and-bound algorithm, is used in extensively searching for the optimal adaptive design with the smallest expected sample size under the null, while the type I and II error rates are maintained and the aforementioned monotonicity characteristic is respected. The proposed optimal design is observed to have smaller expected sample sizes compared to Simon's optimal design, and the maximum total sample size of the proposed adaptive design is very close to that from Simon's method. The proposed optimal adaptive two-stage design is recommended for use in practice to improve the flexibility and efficiency of early phase therapeutic development.
| S-EPMC4777673 | biostudies-literature
Project description:Cost-effective yet efficient designs are critical to the success of biomarker evaluation research. Two-phase sampling designs, under which expensive markers are only measured on a subsample of cases and non-cases within a prospective cohort, are useful in novel biomarker studies for preserving study samples and minimizing cost of biomarker assaying. Statistical methods for quantifying the predictiveness of biomarkers under two-phase studies have been proposed (Cai and Zheng, 2012; Liu, Cai and Zheng, 2012). These methods are based on a class of inverse probability weighted (IPW) estimators where weights are 'true' sampling weights that simply reflect the sampling strategy of the study. While simple to implement, existing IPW estimators are limited by lack of practicality and efficiency. In this manuscript, we investigate a variety of two-phase design options and provide statistical approaches aimed at improving the efficiency of simple IPW estimators by incorporating auxiliary information available for the entire cohort. We consider accuracy summary estimators that accommodate auxiliary information in the context of evaluating the incremental values of novel biomarkers over existing prediction tools. In addition, we evaluate the relative efficiency of a variety of sampling and estimation options under two-phase studies, shedding light on issues pertaining to both the design and analysis of biomarker validation studies. We apply our methods to the evaluation of a novel biomarker for liver cancer risk conducted with a two-phase nested case control design (Lok et al., 2010).
| S-EPMC5604898 | biostudies-literature
Project description:Little attention has been given to the design of efficient studies to evaluate longitudinal biomarkers. Measuring longitudinal markers on an entire cohort is cost prohibitive and, especially for rare outcomes such as cancer, may be infeasible. Thus, methods for evaluation of longitudinal biomarkers using efficient and cost-effective study designs are needed. Case cohort (CCH) and nested case-control (NCC) studies allow investigators to evaluate biomarkers rigorously and at reduced cost, with only a small loss in precision. In this article, we develop estimators of several measures to evaluate the accuracy and discrimination of predicted risk under CCH and NCC study designs. We use double inverse probability weighting (DIPW) to account for censoring and sampling bias in estimation and inference procedures. We study the asymptotic properties of the proposed estimators. To facilitate inference using two-phase longitudinal data, we develop valid resampling-based variance estimation procedures under CCH and NCC. We evaluate the performance of our estimators under CCH and NCC using simulation studies and illustrate them on a NCC study within the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) clinical trial. Our estimators and inference procedures perform well under CCH and NCC, provided that the sample size at the time of prediction (effective sample size) is reasonable. These methods are widely applicable, efficient, and cost-effective and can be easily adapted to other study designs used to evaluate prediction rules in a longitudinal setting.
| S-EPMC6587940 | biostudies-literature
Project description:We develop a nature-inspired stochastic population-based algorithm and call it discrete particle swarm optimization to find extended two-stage adaptive optimal designs that allow three target response rates for the drug in a phase II trial. Our proposed designs include the celebrated Simon's two-stage design and its extension that allows two target response rates to be specified for the drug. We show that discrete particle swarm optimization not only frequently outperforms greedy algorithms, which are currently used to find such designs when there are only a few parameters; it is also capable of solving design problems posed here with more parameters that greedy algorithms cannot solve. In stage 1 of our proposed designs, futility is quickly assessed and if there are sufficient responders to move to stage 2, one tests one of the three target response rates of the drug, subject to various user-specified testing error rates. Our designs are therefore more flexible and interestingly, do not necessarily require larger expected sample size requirements than two-stage adaptive designs. Using a real adaptive trial for melanoma patients, we show our proposed design requires one half fewer subjects than the implemented design in the study.
| S-EPMC5515697 | biostudies-literature
Project description:The COVID-19 pandemic has highlighted the importance of efficient sampling strategies and statistical methods for monitoring infection prevalence, both in humans and in reservoir hosts. Pooled testing can be an efficient tool for learning pathogen prevalence in a population. Typically, pooled testing requires a second-phase retesting procedure to identify infected individuals, but when the goal is solely to learn prevalence in a population, such as a reservoir host, there are more efficient methods for allocating the second-phase samples.To estimate pathogen prevalence in a population, this manuscript presents an approach for data fusion with two-phased testing of pooled samples that allows more efficient estimation of prevalence with less samples than traditional methods. The first phase uses pooled samples to estimate the population prevalence and inform efficient strategies for the second phase. To combine information from both phases, we introduce a Bayesian data fusion procedure that combines pooled samples with individual samples for joint inferences about the population prevalence.Data fusion procedures result in more efficient estimation of prevalence than traditional procedures that only use individual samples or a single phase of pooled sampling.The manuscript presents guidance on implementing the first-phase and second-phase sampling plans using data fusion. Such methods can be used to assess the risk of pathogen spillover from reservoir hosts to humans, or to track pathogens such as SARS-CoV-2 in populations.
| S-EPMC8525136 | biostudies-literature